{"id":"https://openalex.org/W2913454597","doi":"https://doi.org/10.1182/blood-2018-99-113066","title":"SE-7552, a Highly Selective, Non-Hydroxamate Inhibitor of Histone Deacetylase-6 Blocks Multiple Myeloma Growth In Vivo","display_name":"SE-7552, a Highly Selective, Non-Hydroxamate Inhibitor of Histone Deacetylase-6 Blocks Multiple Myeloma Growth In Vivo","publication_year":2018,"publication_date":"2018-11-29","ids":{"openalex":"https://openalex.org/W2913454597","doi":"https://doi.org/10.1182/blood-2018-99-113066","mag":"2913454597"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2018-99-113066","doi":"https://doi.org/10.1182/blood-2018-99-113066","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-113066","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5011265491","display_name":"Jason A. Holt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Jason A Holt","raw_affiliation_strings":["Selenity Therapeutics, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Selenity Therapeutics, Durham, NC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110166075","display_name":"Edward P. Garvey","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Edward P Garvey","raw_affiliation_strings":["Selenity Therapeutics, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Selenity Therapeutics, Durham, NC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022540344","display_name":"J. David Becherer","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"J. David Becherer","raw_affiliation_strings":["Selenity Therapeutics, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Selenity Therapeutics, Durham, NC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103475104","display_name":"William J. Hoekstra","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"William J Hoekstra","raw_affiliation_strings":["Selenity Therapeutics, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Selenity Therapeutics, Durham, NC","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5073464082","display_name":"Robert J. Schotzinger","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Robert J Schotzinger","raw_affiliation_strings":["Selenity Therapeutics, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Selenity Therapeutics, Durham, NC","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5083348242","display_name":"Christopher M. Yates","orcid":"https://orcid.org/0000-0003-0884-1122","observed_orcids":["https://orcid.org/0000-0003-0884-1122"]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"Christopher M Yates","raw_affiliation_strings":["Selenity Therapeutics, Durham, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Selenity Therapeutics, Durham, NC","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":["https://openalex.org/A5011265491","https://openalex.org/A5022540344","https://openalex.org/A5073464082","https://openalex.org/A5083348242","https://openalex.org/A5103475104","https://openalex.org/A5110166075"],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"132","issue":"Supplement 1","first_page":"3215","last_page":"3215"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11736","display_name":"Histone Deacetylase Inhibitors Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12412","display_name":"Enzyme function and inhibition","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/hdac6-inhibitors","display_name":"HDAC6 inhibitors","score":0.8489999771118164},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9139999747276306},{"id":"https://openalex.org/keywords/zinc-binding-group","display_name":"zinc-binding groups","score":0.722000002861023},{"id":"https://openalex.org/keywords/hdac-isoform-selectivity","display_name":"HDAC isoform selectivity","score":0.7419999837875366},{"id":"https://openalex.org/keywords/alpha-tubulin-acetylation","display_name":"alpha-tubulin acetylation","score":0.8619999885559082},{"id":"https://openalex.org/keywords/ricolinostat","display_name":"ricolinostat","score":0.8209999799728394},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7549999952316284},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.7149999737739563},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.6010000109672546},{"id":"https://openalex.org/keywords/drug-toxicity","display_name":"drug toxicity","score":0.3330000042915344},{"id":"https://openalex.org/keywords/anticancer-drug-discovery","display_name":"anticancer drug discovery","score":0.5789999961853027},{"id":"https://openalex.org/keywords/medicinal-chemistry","display_name":"medicinal chemistry","score":0.367000013589859}],"concepts":[{"id":"https://openalex.org/C2780225316","wikidata":"https://www.wikidata.org/wiki/Q7131441","display_name":"Panobinostat","level":5,"score":0.6756138801574707},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.5986667275428772},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5787104368209839},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5126127600669861},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.49442005157470703},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4754086136817932},{"id":"https://openalex.org/C2781462825","wikidata":"https://www.wikidata.org/wiki/Q7363205","display_name":"Romidepsin","level":5,"score":0.47075846791267395},{"id":"https://openalex.org/C23681527","wikidata":"https://www.wikidata.org/wiki/Q18034953","display_name":"HDAC6","level":5,"score":0.4684695601463318},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.30393674969673157},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.30160588026046753},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.19404470920562744},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2018-99-113066","doi":"https://doi.org/10.1182/blood-2018-99-113066","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2018-99-113066","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":0.9391000270843506,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2055588591","https://openalex.org/W7116790993","https://openalex.org/W2568000729","https://openalex.org/W2606526595","https://openalex.org/W4317936629","https://openalex.org/W2782381116","https://openalex.org/W3194311760","https://openalex.org/W2339970372","https://openalex.org/W2594684674","https://openalex.org/W2532183495"],"abstract_inverted_index":{"Abstract":[0],"Despite":[1],"recent":[2],"advances,":[3],"disease":[4],"progression":[5],"and":[6,26,57,59,110,132,153,168,186,215,231,256,283,401,547,566],"treatment":[7],"resistance":[8],"in":[9,158,172,209,297,305,316,399,402,454,468,502,511,560,562,570],"multiple":[10,178],"myeloma":[11],"(MM)":[12],"remains":[13],"a":[14,99,139,148,164,194,222,247,277,284,290,331,353,438,495,521,539],"significant":[15,155],"challenge.":[16],"Current":[17],"therapies":[18],"include":[19],"proteasome":[20],"inhibitors,":[21,275],"immunomodulatory":[22],"agents,":[23],"monoclonal":[24],"antibodies":[25],"more":[27],"recently":[28],"histone":[29],"deacetylase":[30],"(HDAC)":[31],"inhibitors.":[32,553],"Many":[33],"HDAC":[34,72,129,145,265,274],"inhibitors":[35,54,73,418],"have":[36,537],"progressed":[37,407],"into":[38,408],"clinical":[39],"development,":[40],"however,":[41],"there":[42],"has":[43,74,105,154,163,177],"been":[44,75,106],"limited":[45,128],"success":[46],"with":[47,108,200,228,249,276,322,432,456,513,544,576],"the":[48,60,69,76,94,97,121,142,173,191,219,238,243,298,317,325,367,375,390,397,480,483],"approval":[49],"of":[50,71,78,81,87,96,120,141,150,193,205,221,237,245,252,280,286,294,303,319,335,341,377,383,392,412,482,498,558,637,651,666],"only":[51],"three":[52],"pan-HDAC":[53],"(SAHA,":[55],"belinostat":[56],"panobinostat)":[58],"class":[61,143],"I":[62,385],"selective":[63],"inhibitor,":[64,328,542],"romidepsin.":[65],"A":[66],"challenge":[67],"to":[68,93,123,127,136,218,242,272,422,470,528,550],"development":[70],"management":[77],"toxicities,":[79],"many":[80],"which":[82,503],"are":[83],"dose":[84,293,334,357],"limiting.":[85],"Some":[86],"these":[88],"toxicities":[89],"can":[90,490],"be":[91,491],"attributed":[92],"use":[95],"hydroxamate,":[98],"potent":[100],"zinc":[101,124],"binding":[102,118],"group":[103,224],"that":[104,225,489],"associated":[107,227],"toxicity":[109],"poor":[111],"pharmacokinetic":[112],"(PK)":[113],"properties.":[114],"The":[115],"very":[116],"tight":[117],"potency":[119,230],"hydroxamate":[122],"also":[125],"leads":[126],"isoform":[130],"selectivity":[131,232,260,546,559],"thus":[133],"further":[134],"predisposes":[135],"toxicity.":[137],"HDAC6,":[138],"member":[140],"IIb":[144],"family,":[146],"is":[147,169],"target":[149],"high":[151,556],"interest":[152],"therapeutic":[156],"potential":[157],"oncology,":[159],"particularly":[160],"MM.":[161,413],"It":[162],"unique":[165],"protein":[166,180],"structure":[167],"predominantly":[170],"located":[171],"cytoplasm":[174],"where":[175],"it":[176],"non-histone":[179],"substrates":[181],"including":[182],"\u03b1-tubulin,":[183],"HSP90,":[184],"cortactin,":[185],"Foxp3.":[187],"Here,":[188],"we":[189,536],"describe":[190],"identification":[192,244],"highly":[195],"selective,":[196],"non-hydroxamate":[197,540],"HDAC6":[198,255,304,312,327,417,541,552],"inhibitor":[199],"excellent":[201,229],"PK":[202,270],"properties":[203],"capable":[204],"inhibiting":[206],"MM":[207,425,440,445,499,568,578],"growth":[208,426,467,526,569],"vivo.":[210],"Extensive":[211],"medicinal":[212],"chemistry":[213],"exploration":[214],"optimization":[216,236],"led":[217,241],"discovery":[220],"zinc-binding":[223],"was":[226,314,406,430,500],"for":[233,311,346,361,381],"HDAC6.":[234],"Additional":[235],"chemical":[239],"scaffold":[240],"SE-7552,":[246,543],"compound":[248],"an":[250,561,634,648,663],"IC50":[251],"33nM":[253],"against":[254],"greater":[257],"than":[258,363],"850-fold":[259],"versus":[261],"all":[262],"other":[263],"known":[264],"isozymes.":[266],"SE-7552":[267,323,336,370,405,429,447,504,554],"demonstrated":[268,555],"superior":[269,545],"compared":[271,527,549],"hydroxamate-based":[273,326],"maximum":[278],"exposure":[279],"597":[281],"ng/ml":[282],"half-life":[285],"7.2":[287],"hours":[288],"after":[289],"single":[291,332],"oral":[292,333],"5":[295],"mg/kg":[296,355,452,461,509,518],"mouse.":[299],"To":[300],"characterize":[301],"inhibition":[302,382],"vivo,":[306],"acetylated":[307,342,393],"\u03b1-tubulin":[308,343],"(a":[309,379],"biomarker":[310,380,564],"inhibition)":[313],"measured":[315],"spleen":[318],"mice":[320],"treated":[321],"or":[324,435,639,653,668],"ricolinostat.":[329],"After":[330],"at":[337,352,450,459,507,516],"30":[338],"mg/kg,":[339],"levels":[340,360,391,557],"were":[344,419],"increased":[345,359,389],"over":[347],"24":[348],"hours,":[349],"whereas":[350,387],"ricolinostat":[351,388],"50":[354],"IP":[356,462,519],"showed":[358],"less":[362],"8":[364],"hours.":[365],"In":[366,437,534],"same":[368],"study,":[369],"had":[371],"no":[372],"effect":[373],"on":[374,396,633,647,662],"acetylation":[376],"H3":[378],"Class":[384],"HDACs),":[386],"H3.":[394],"Based":[395],"positive":[398],"vitro":[400],"vivo":[403,563],"profile,":[404],"pre-clinical":[409,572],"rodent":[410],"models":[411,573],"Since":[414],"previously":[415],"studied":[416],"not":[420],"able":[421],"significantly":[423,464,523],"inhibit":[424],"as":[427,476,478],"monotherapy,":[428],"co-administered":[431,575],"either":[433],"pomalidomide":[434,457,471],"bortezomib.":[436],"subcutaneous":[439],"model":[441,497],"using":[442],"human":[443,486],"H929":[444],"cells,":[446],"dosed":[448,458,505,515],"orally":[449,506],"10":[451,508],"daily":[453,463,510],"combination":[455,512],"1":[460],"delayed":[465,524],"tumor":[466,525],"comparison":[469],"alone":[472,530],"(p":[473,531],"<":[474,532],"0.01),":[475],"well":[477],"enhanced":[479],"survival":[481],"mice.":[484],"Utilizing":[485],"MM.1S":[487],"cells":[488],"quantified":[492],"by":[493],"luminescence,":[494],"disseminated":[496],"conducted":[501],"bortezomib":[514,529],"1.5":[517],"once":[520],"week":[522],"0.05).":[533],"summary,":[535],"identified":[538],"pharmacokinetics":[548],"current":[551,577],"study":[565],"blocked":[567],"two":[571],"when":[574],"therapies.":[579],"Disclosures":[580],"Holt:":[581],"Selenity":[582,656],"Therapeutics:":[583,602,607,612,657,686],"Employment,":[584,603,608,613,658,687],"Equity":[585,604,609,614,644,659,688],"Ownership,":[586,615,645,660,689],"Patents":[587,616,671,690],"&":[588,617,672,691],"Royalties:":[589,618,673,692],"METALLOENZYME":[590,619,674,693],"INHIBITOR":[591,620,675,694],"COMPOUNDS,":[592,621,676,695],"U.S.":[593,622,677,696],"Patent":[594,623,678,697],"Application":[595,624,679,698],"No.:":[596,625,680,699],"15/917,555":[597,626,681,700],"(March":[598,627,682,701],"9,":[599,628,683,702],"2018).":[600,629,684,703],"Garvey:Selenity":[601],"Ownership.":[605,610],"Becherer:Selenity":[606],"Hoekstra:Selenity":[611],"Schotzinger:Mycovia":[630],"Pharma:":[631,643],"Membership":[632,646,661],"entity's":[635,649,664],"Board":[636,650,665],"Directors":[638,652,667],"advisory":[640,654,669],"committees;":[641,655],"Innocrin":[642],"committees,":[670],"Yates:Selenity":[685]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":1}],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2019-02-21T00:00:00"}